Article
Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
The Journal of clinical investigation - 17 Oct 2022
Nie Meng, Chen Na, Pang Huanhuan, Jiang Tao, Jiang Wei, Tian Panwen, Yao LiAng, Chen Yangzi, DeBerardinis Ralph J, Li Weimin, Yu Qitao, Zhou Caicun, Hu Zeping
Abstract excerpt
Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is effective for treating EGFR-mutant non-small cell lung cancer (NSCLC), it is now understood that drug-tolerant persister (DTP) cells escaping from initial treatment eventually drives drug resistance. Here, through integration of metabolomics and transcriptomics, we found that the neurotransmitter acetylcholine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.